June 23, JMP Securities Healthcare Conference

Transcription

1 June 23, 2015 JMP Securities Healthcare Conference

2 Safe Harbor Statement The following presentation includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of You should be aware that our actual results could differ materially from those contained in the forward looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the rate and degree of market acceptance of, and our ability and our distribution and marketing partners ability to obtain coverage and reimbursement for, any approved products; our ability to successfully execute our sales and marketing strategy, including to continue to successfully recruit and retain sales and marketing personnel in the U.S.; risks associated with our acquisition of certain assets related to the product Zohydro ER from Zogenix, Inc. ( Zogenix ), and the hiring of certain employees of Zogenix related to the Zohydro ER business, including our success in hiring certain of the Zohydro Employees and ability to manage such employees, and our ability to successfully integrate the Zohydro ER business into our operations and realize the anticipated benefits of this acquisition; our ability to obtain additional financing; our ability to maintain regulatory approvals for our products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to manage our anticipated future growth; the ability of our products to compete with generic products as well as new products that may be developed by our competitors; our ability to comply with regulatory requirements regarding the sales, marketing and manufacturing of our products; the performance of our manufacturers, over which we have limited control; our ability and the ability of our partners to obtain and maintain intellectual property protection for our products; our ability to operate our business without infringing the intellectual property rights of others; the success and timing of our clinical development efforts; the loss of key scientific or management personnel; regulatory developments in the U.S. and foreign countries; our ability to either acquire or develop and commercialize other product candidates in addition to our current products; and other risks detailed in the section titled Item 1A. Risk Factors in the Company s Annual Report on Form 10-K for the year ended December 31, You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Pernix is a registered trademark of Pernix Therapeutics, LLC. Other trademarks referenced herein are the property of their respective owners Pernix Therapeutics Holdings, Inc. 2

3 Investment Highlights Rapidly growing specialty pharmaceutical company In-market products & pipeline opportunities focused in pain & CNS markets Dedicated 200-person specialty sales force building 3 core brands Proven, integrated commercial platform Compelling financial performance Attractive pipeline of business development opportunities in target markets 3

4 Accelerating Financial Performance May 2014: Re-launched August 2014: Acquired CNS product from GSK Evaluating 30+ opportunities in specialty areas April 2015: Acquired from Zogenix $250 $200 April 2014: Licensing agreement with Osmotica $220 - $240m 1) in millions $150 $100 $50 $0 -$50 $122 $85 $45 - $55m 1) $ A 2013A 2014A 2015E Revenue Adjusted EBITDA 1) 4 (1) 2015E net sales based on mid-point of guidance for $220 million - $240 million; Adj. EBITDA based on mid-point of guidance for $45 million - $55 million

5 Pernix Commercial Footprint Pernix Sales Force (200) Neuroscience Specialty Sales Force Pain Management Specialty Sales Force 5 Further leverage through future acquisitions

6 Large Market Opportunities 14.8 million triptan prescriptions dispensed in % market share by volume 1% market share gain equals $110m of sales 40 million people experience sleep problems in the U.S. 0.2% market share by volume Limited competitive promotion and sampling 1% market share gain adds $160m of sales 114 million hydrocodone/apap TRx in 2014 in the U.S. ~30% for chronic pain 1% of hydrocodone/apap TRx adds $430m of sales BeadTek launched in May

7 Treximet Progress (weekly TRx) Weekly TRx Chart Growth Strategy / Tactics Samples become available to sales force Sampling started week of 3/23 Marketing activities ramping in 2Q Pernix Pharmacy Direct Pernix Therapeutics closes acquisition of Treximet and begins promotion Call deck optimized 7 Source: Symphony Health Source Pharmaceutical Audit Suite (PHAST).

8 Treximet Progress (weekly TRx $) $6.0 $5.0 $4.0 Millions $3.0 $2.0 $1.0 $0.0 Data source: Bloomberg Treximet Retail TRx $ 8 Source: Symphony Health Source Pharmaceutical Audit Suite (PHAST).

9 Silenor Progress (weekly Rx) Weekly TRx Chart Growth Strategy / Tactics 3,500 3,000 2,500 Silenor Re-launch Silenor Consumer Engagement Added 100 sales reps May 4, 2015 through acquisition of Zohydro ER Conversion of GABA agonist market Pernix Pharmacy Direct 2,000 Consumer awareness is a priority in ,500 1,000 04/11/14 04/25/14 05/09/14 05/23/14 06/06/14 06/20/14 07/04/14 07/18/14 08/01/14 08/15/14 08/29/14 09/12/14 09/26/14 10/10/14 10/24/14 11/07/14 11/21/14 12/05/14 12/19/14 01/02/15 01/16/15 01/30/15 02/13/15 02/27/15 03/13/15 03/27/15 04/10/15 04/24/15 05/08/15 05/22/15 06/05/15 9 Source: Symphony Health Source Pharmaceutical Audit Suite (PHAST)

10 Silenor Progress (weekly TRx $) $1.2 $1.0 $0.8 Millions $0.6 $0.4 $0.2 $ Source: Symphony Health Source Pharmaceutical Audit Suite (PHAST).

11 Zohydro ER Launch Progress PTX inherited two major hurdles to script growth Pharmacy stocking Payer access Pharmacy Stocking Rapid actions have resulted in 99% of PTX trade customers ordering Zohydro ER with BeadTek 2nd and 3rd largest US pharmacy chains were previously not stocking Zohydro ER All US pharmacy chains now filling Zohydro ER with BeadTek scripts Payer Access Proposals have been submitted to all major PBMs with initial favorable reaction 15 HMO Managed Care decisions to remove restrictions are pending All existing contracts have been transferred to prevent coverage gaps 11

12 Zohydro ER Snapshot (weekly Rx) Weekly TRx Chart Growth Strategy / Tactics 2,000 1,800 1,600 1,400 1,200 1, Zohydro ER acquisition closed 5/4 launched Zohydro ER with BeadTek Transitioning to Zohydro ER with BeadTek PBMs and pharmacies removing from restricted list Improve managed care access Capture hydrocodone/apap chronic pain Rx Leverage synergies with CNS portfolio 4/11/14 4/25/14 5/9/14 5/23/14 6/6/14 6/20/14 7/4/14 7/18/14 8/1/14 8/15/14 8/29/14 9/12/14 9/26/14 10/10/14 10/24/14 11/7/14 11/21/14 12/5/14 12/19/14 1/2/15 1/16/15 1/30/15 2/13/15 2/27/15 3/13/15 3/27/15 4/10/15 4/24/15 5/8/15 5/22/15 6/5/15 12

13 Pernix Pharmacy Direct Program Enables script ownership from time it is written to when it is filled Eliminates abandonment between physician and pharmacy, increasing script fulfillment and refills 25% increase in fill rate in pilot cities Switch whole practices from zolpidem / eszopiclone to Silenor and from sumatriptan to Treximet Provide access to our products more broadly and avoid negative feedback loop to physicians Enables closer relationship with our patients 13

14 IP / Life Cycle Management Strategy Pediatric exclusivity granted 4/16 LCM Four Orange Book patents OTC Switch BeadTek ZX007 (Altus) (1) Patent Expiry Lifecycle Management 14 1) Patent rights acquired through the Zohydro ER acquisition expire in 2019 and also include the right to license additional patents from Altus that extend coverage for the ZX007 product to 2029.

15 Accelerating Financial Performance May 2014: Re-launched August 2014: Acquired CNS product from GSK Evaluating 30+ opportunities in specialty areas April 2015: Acquired from Zogenix $250 $200 April 2014: Licensing agreement with Osmotica $220 - $240m 1) in millions $150 $100 $50 $0 -$50 $122 $85 $45 - $55m 1) $ A 2013A 2014A 2015E Revenue Adjusted EBITDA 1) 15 (1) 2015E net sales based on mid-point of guidance for $220 million - $240 million; Adj. EBITDA based on mid-point of guidance for $45 million - $55 million

16 Why Pernix? Why Now? Rapidly growing specialty pharmaceutical company In-market products & pipeline opportunities focused in pain & CNS markets Dedicated 200-person specialty sales force building 3 core brands Core brands address large market opportunities with significant growth potential Proven, integrated commercial platform Intellectual property and lifecycle management strategy to provide extended longevity for core brands Compelling financial performance Attractive pipeline of business development opportunities in target markets 16

17 Thank You 17